Arecor Therapeutics PLC - Asset Resilience Ratio

Latest as of June 2025: 0.36%

Arecor Therapeutics PLC (AREC) has an Asset Resilience Ratio of 0.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Arecor Therapeutics PLC carry for a breakdown of total debt and financial obligations.

Liquid Assets

GBX19.00K

≈ $2.31 USD Cash + Short-term Investments

Total Assets

GBX5.25 Million

≈ $638.77 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how Arecor Therapeutics PLC's Asset Resilience Ratio has changed over time. See net assets of Arecor Therapeutics PLC for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Arecor Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AREC stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX19.00K	0.36%
Total Liquid Assets	GBX19.00K	0.36%

Asset Resilience Insights

Limited Liquidity: Arecor Therapeutics PLC maintains only 0.36% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Arecor Therapeutics PLC Industry Peers by Asset Resilience Ratio

Compare Arecor Therapeutics PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	35.56%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Arecor Therapeutics PLC (2022–2024)

The table below shows the annual Asset Resilience Ratio data for Arecor Therapeutics PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.21%	GBX18.00K ≈ $2.19	GBX8.72 Million ≈ $1.06K	-10.58pp
2023-12-31	10.79%	GBX1.66 Million ≈ $201.85	GBX15.38 Million ≈ $1.87K	-26.16pp
2022-12-31	36.94%	GBX8.04 Million ≈ $978.36	GBX21.77 Million ≈ $2.65K	--

pp = percentage points

About Arecor Therapeutics PLC

LSE:AREC UK Biotechnology

Market Cap

$303.20K

GBX2.49 Billion GBX

Market Cap Rank

#30716 Global

#974 in UK

Share Price

GBX66.00

Change (1 day)

+0.00%

52-Week Range

GBX38.00 - GBX92.50

All Time High

GBX450.00